Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kindstar Globalgene Technology's quarterly market cap
increased
from Dec. 2024 (HK$1,150 Mil) to Jun. 2025 (HK$1,406 Mil) but then
declined
from Jun. 2025 (HK$1,406 Mil) to Dec. 2025 (HK$1,158 Mil).
Kindstar Globalgene Technology's annual market cap
declined
from Dec. 2023 (HK$1,656 Mil) to Dec. 2024 (HK$1,150 Mil) but then
increased
from Dec. 2024 (HK$1,150 Mil) to Dec. 2025 (HK$1,158 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Kindstar Globalgene Technology's Enterprise Value for Today is HK$-225 Mil.
Kindstar Globalgene Technology (HKSE:09960) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Kindstar Globalgene Technology Market Cap Related Terms
Kindstar Globalgene Technology Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:09960 vs TMO, DHR, NTRA: Market Cap Comparison
For the Diagnostics & Research subindustry, Kindstar Globalgene Technology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kindstar Globalgene Technology Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Kindstar Globalgene Technology's Market Cap distribution charts can be found below:
* The bar in red indicates where Kindstar Globalgene Technology's Market Cap falls into.
Kindstar Globalgene Technology Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kindstar Globalgene Technology (HKSE:09960) has a Market Cap of HK$1,033 Mil as of Aug. 31, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Kindstar Globalgene Technology and its competitors. According to the industry distribution chart, Kindstar Globalgene Technology ranks #96 out of 218 companies in the Medical Diagnostics & Research industry, placing it in the top 44%.
Is Kindstar Globalgene Technology's Market Cap too high?
Kindstar Globalgene Technology's current Market Cap is HK$1,033 Mil. Based on the distribution chart, Kindstar Globalgene Technology ranks #96 out of 218 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Kindstar Globalgene Technology has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kindstar Globalgene Technology's Market Cap compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Kindstar Globalgene Technology ranks #96 out of 218 companies for Market Cap. This puts Kindstar Globalgene Technology in the upper half of its industry. The industry median Market Cap is 64.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 64.58, based on 218 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Kindstar Globalgene Technology and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 64.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kindstar Globalgene Technology's current Market Cap is HK$1,033 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kindstar Globalgene Technology stock overvalued right now?
Based on GuruFocus' analysis, Kindstar Globalgene Technology (HKSE:09960) is currently considered Fairly Valued. The stock's GF Value™ is HK$1.06, compared to a current price of HK$1.00 — trading 5.7% below its estimated fair value. The current Market Cap is HK$1,033 Mil. Kindstar Globalgene Technology's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Kindstar Globalgene Technology (HKSE:09960), the current Market Cap is HK$1,033 Mil as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kindstar Globalgene Technology (HKSE:09960) Overvalued in 2026?
Based on GuruFocus' analysis, Kindstar Globalgene Technology stock appears to be undervalued.
The current stock price of HK$1.00 is trading 5.7% below its estimated GF Value™ of HK$1.06.
GuruFocus considers Kindstar Globalgene Technology to be Fairly Valued.
Key valuation signals for HKSE:09960:
Market Cap: HK$1,033 Mil
GF Value™: HK$1.06 vs. price of HK$1.00 (5.7% below fair value)
No single metric tells the full story. See the HKSE:09960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kindstar Globalgene Technology Inc is engaged in the provision of clinical testing services in China. It operates in nine segments: Hematology testing segment includes testing services related to blood diseases; Genetic diseases and rare diseases segment includes testing services for rare diseases; Infectious diseases segment includes testing services from the infection department; Oncology segment includes testing related to oncology diseases; Neurology segment includes testing services related to neurological diseases undertaken by the Group; Maternity-related diseases segment includes testing services related to maternity; Routine testing segment conducts routine tests for the doctors daily diagnoses; CROs & R&D project segment includes research & develop services; & others segment.
69GF Score
Get the complete analysis for HKSE:09960
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09960 has been successfully added to your 
